ClinicalTrials.Veeva

Menu
S

San Juan Oncology Associates | Farmington, NM

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Trastuzumab
Obinutuzumab
Atezolizumab
Pertuzumab
Dexamethasone
Paclitaxel
Carboplatin
Lenalidomide
Erlotinib
Docetaxel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 61 total trials

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MD...

Enrolling
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Drug: SEA-CD70
Drug: azacitidine

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Palbociclib
Drug: Giredestrant

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your b...

Enrolling
HER2 Positive Breast Neoplasms
HER2 Low Breast Neoplasms
Drug: tucatinib
Drug: disitamab vedotin

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 ye...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Ixazomib

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only
Solid Tumor
Graft Vs Host Disease
Drug: Ibrutinib

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irino...

Active, not recruiting
Metastatic Colorectal Cancer
Colorectal Cancer
Drug: Bevacizumab
Drug: Onvansertib

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.

Enrolling
Blood Platelet Disorder
Thrombocytopenia
Drug: HMPL-523

Trial sponsors

Genentech logo
Roche logo
Seagen logo
M
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Merck KGaA (EMD Serono) logo
Novartis logo
Takeda logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems